Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CytoSorbentsSTU:HQE 45 5-Year Yield-on-Cost % is 0.00 as of Sep. 11, 2026. GuruFocus rates STU:HQE with a GF Score™ of 45/100 and a GF Value™ of €16.19. The stock has 5 warning signs investors should review. Among 314 Medical Devices & Instruments companies, CytoSorbents ranks worse than 318471.02% on this metric.
CytoSorbents's yield on cost for the quarter that ended in Jun. 2026 was 0.00.
The historical rank and industry rank for CytoSorbents's 5-Year Yield-on-Cost % or its related term are showing as below:
STU:HQE's 5-Year Yield-on-Cost % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.5 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
CytoSorbents 5-Year Yield-on-Cost % Related Terms
STU:HQE vs LFWD, GTHP, PMI: 5-Year Yield-on-Cost % Comparison
For the Medical Devices subindustry, CytoSorbents's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CytoSorbents 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, CytoSorbents's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where CytoSorbents's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of CytoSorbents is calculated as
CytoSorbents (STU:HQE) has a 5-Year Yield-on-Cost % of 0.00 as of Sep. 11, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on CytoSorbents and its competitors. According to the industry distribution chart, CytoSorbents ranks #999999 out of 314 companies in the Medical Devices & Instruments industry.
Is CytoSorbents' 5-Year Yield-on-Cost % too high?
CytoSorbents' current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, CytoSorbents ranks #999999 out of 314 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, CytoSorbents has a GF Score™ of 45/100, reflecting its overall financial health beyond just this single metric.
How does CytoSorbents' 5-Year Yield-on-Cost % compare to LFWD and GTHP?
According to the Medical Devices & Instruments industry distribution chart, CytoSorbents ranks #999999 out of 314 companies for 5-Year Yield-on-Cost %. This places CytoSorbents in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.50, based on 314 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on CytoSorbents and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CytoSorbents's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytoSorbents stock overvalued right now?
CytoSorbents (STU:HQE) has a current 5-Year Yield-on-Cost % of 0.00. The stock's GF Value™ is €16.19, compared to a current price of €5.92 — trading 63.4% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. CytoSorbents' overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For CytoSorbents (STU:HQE), the current 5-Year Yield-on-Cost % is 0.00 as of Sep. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CytoSorbents (STU:HQE) Overvalued in 2026?
Based on GuruFocus' analysis, CytoSorbents stock appears to be undervalued.
The current stock price of €5.92 is trading 63.4% below its estimated GF Value™ of €16.19.
Key valuation signals for STU:HQE:
5-Year Yield-on-Cost %: 0.00
GF Value™: €16.19 vs. price of €5.92 (63.4% below fair value)
No single metric tells the full story. See the STU:HQE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbent's technologies are used in several broad applications. Specifically, two important applications are: the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and the removal of inflammatory agents and toxins in common critical illnesses that can cause massive inflammation, organ failure, and patient death. Geographically, in the USA, Germany, and Others.
45GF Score
Get the complete analysis for STU:HQE
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:HQE has been successfully added to your 
